Page 40 - index

Fibrillazione Atriale in Medicina Generale

Bibliografa fbrillazione atriale non valvolare e score di rischio
1 van Weert HC. Diagnosing atrial fbrillation in gen- trombo-embolico: ATA-AF Survey. G Ital Cardiol
eral practice. BMJ 2007;335:355-6. 2011;5(Suppl 1):5-6S.
15 Ogilvie IM, Newton N, Welner SA, et al. Underuse
2 Wolf PA, Dawber TR, Thomas HE, et al. Epidemio-
logical assessment of chronic atrial fbrillation and of oral anticoagulants in atrial fbrillation: a system-
the risk of stroke: the Framingham Study. Neurol- atic review. Am J Med 2010;123:638-45.
ogy 1978;28:973-7. 16 Mazzaglia G, Filippi A, Alacqua M, et al. A nation-
3 Connolly SJ, Eikelboom JW, Ng J et al. Net clini- al survey of the management of atrial fbrillation
cal beneft of adding clopidogrel to aspirin therapy with antithrombotic drugs in Italian primary care.
Thromb Haemost 2010;103:968-75.
in patients with atrial fbrillation for whom vitamin
K antagonists are unsuitable. Ann Intern Med 17 Broderick JP, Bonomo JB, Kissela BM, et al. With-
2011;155:579-86. drawal of antitrombotic agents and its impact on
4 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: an- ischemic stroke occurrence. Stroke 2011;42:2509-
tithrombotic therapy to prevent strokes in patients 18 14.
who have nonvalvular etrial fbrillation. Ann Int Med Zoni Berisso M, Filippi A, Landolina M, et al. Fre-
2007;146:857-67. quency, patient characteristics, treatment strate-
5 Ogilvie IM, Welner SA, Cowell W, et al. Ischaemic gies and re source utilization of atrial fbrillation
stroke and bleeding rates in ‘real-world’ atrial fbril- (from the Italian Survey of Atrial Fibrillation manage-
ment [ISAF] study). Am J Cardiol 2013;111:705-11.
lation patients. Thromb Haemost 2011;106:34-44.
6 Mant J, Hobbs FD, Fletcher K et al. Warfarin vs. 19 Wilke T, Groth A, Mueller S et al. Oral anticoagula-
aspirin for stroke prevention in an elderly commu- tion use by patients with atrial fbrillation in Germa-
ny. Adherence to guidelines, causes of anticoagula-
nity population with atrial fbrillation (the Birming- tion under-use and its clinical aoucomes, based on
ham Atrial Fibrillation Treatment of the AGED Study. daims-data of 183,448 patients. Thromb Haemost
BAFTA): a randomized controlled trial. Lancet 2012;107:1053-65.
2007;370:493-503.
20 Bradley BC, Perdue KS, Tisdel CA, et al. Frequency
7 Lip GY. The role of aspirin for stroke prevention in of anticoagulation for atrial fbrillation and reasons
atrial fbrillation. Nat Rev Cardiol 2011;8:602-6. for its non-use at a veterans affairs medical center.
8 Camm JA, Lip GYH, De Caterina R, et al. 2012 Am J Cardiol 2000;85:568-72.
focused update of the ESC Guidelines for the 21 Deplanque D, Leys D, Parnetti L, et al. Stroke pre-
management of atrial fbrillation. Eur Heart J vention and atrial fbrillation: reasons leading to an
2012;33:2719-47. inappropriate management. Main results of the
9 Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines SAFE II study. Br J Clin Pharmacol 2004;57:798-
for the management of atrial fbrillation. Eur heart J 806.
2010;32:2369-429. 22 Ingelard A, Hollowell J, Reddy P, et al. What are the
10 Pamukcu B, Lip GYH, Lane DA. Simplifying stroke barriers to warfarin use in atrial fbrillation? Devel-
risk stratifcation in atrial fbrillation patients: impli- opment of a questionnaire. J Thromb Thrombolysis
cations of the CHA DS -VASc risk stratifcation 2006;21:257-65.
2
2
scores. Age Ageing 2010;39:533-5. 23 Baczek VL, Chen WT, Kluger J, et al. Predictors of
11 Olesen JB, Lyp GY, Hansen ML, et al. Validation of warfarin use in atrial fbrillation in the United States:
risck stratifcation schemes for predicting stroke and a systematic review and meta-analysis. BMC Fam-
thromboembolism in patients with atrial fbrillation: ily Practice 2012;13:5-18.
nationwide cohort study. BMJ 2011;342:d124. 24 Apostolakis B, Lane DA, Guo Y, et al. Performance
12 You JJ, Singer DE, Howard PA, et al.; American of the HEMORRAGES, ATRIA and HAS-BLED
College of Chest Physicians. Antithrombotic ther- bleeding risk predicition scores in anticoagulated
apy for atrial fbrillation: antithrombotic therapy for patients with atrial fbrillation: the AMADEUS study.
atrial fbrillation: antithrombotic therapy and pre- J Am Coll Cardiol 2012;60:861-86.
vention of thrombosis, 9th ed: American College of 25 Pisters R, DA Lane, Nieuwlaat R, et al. A novel user-
Chest Physicians evidence-based clinical practice friendly score (HAS-BLED) to assess 1-year risk of
guidelines. Chest 2012;141:e531S-75. major bleeding in patients with atrial fbrillation: the
13 Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ Euro Heart Survey. Chest 2010;138:1093-100.
ESC 2006 guidelines for the management of pa- 26 Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of
tients with atrial fbrillation-Executive summary. J thrombo-embolism and bleeding with thrombopro-
Am Coll Cardiol 2006;48:854-906. phylaxis in patients with atrial fbrillation: a net clini-
14 Colletta M, Perrone C, D’Arienzo E, et al. Prescri- cal beneft analysis using a ‘real world’ nationwide
zione dei trattamenti antitrombotici in pazienti con cohort study. Thromb Haemost 2011;106:739-49.

38